Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vulvovaginal candidosis.

G R Kinghorn1

  • 1Department of Genito-Urinary Medicine, Royal Hallamshire Hospital, Sheffield, UK.

The Journal of Antimicrobial Chemotherapy
|July 1, 1991
PubMed
Summary
This summary is machine-generated.

Vulvovaginal candidosis, a common fungal infection, is rising. Effective treatments include topical antifungals and oral fluconazole, with prophylaxis for recurrent cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mollaret's meningitis and herpes simplex virus type 2 infections.

International journal of STD & AIDS·2011
Same author

Nodular herpes simplex virus-1-positive oral lesions as a manifestation of immune reconstitution inflammatory syndrome.

International journal of STD & AIDS·2010
Same author

Mannose-binding lectin is present in human semen and modulates cellular adhesion of Neisseria gonorrhoeae in vitro.

Clinical and experimental immunology·2009
Same author

Herpesvirus vaccines: an update.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

BASHH survey of additional genitourinary medicine-targeted allocations in 2003 and 2004.

International journal of STD & AIDS·2004
Same author

Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts.

Sexually transmitted infections·2003
Same journal

β-lactam susceptibility testing of ampicillin-susceptible non-faecalis enterococcal clinical isolates in France.

The Journal of antimicrobial chemotherapy·2026
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Area of Science:

  • Mycology
  • Infectious Diseases
  • Women's Health

Background:

  • Vulvovaginal candidosis (VVC) incidence is increasing globally.
  • While often causing temporary discomfort, recurrent VVC can be disabling.
  • Incomplete knowledge of pathogenesis necessitates improved management strategies.

Purpose of the Study:

  • To review current knowledge on VVC pathogenesis, predisposing factors, and clinical features.
  • To evaluate the efficacy and safety of various antifungal treatments for VVC.
  • To discuss management strategies for chronic or recurrent VVC.

Main Methods:

  • Literature review of studies on VVC pathogenesis, epidemiology, and treatment.
  • Analysis of clinical trial data for topical and oral antifungal therapies.

Related Experiment Videos

  • Evaluation of prophylactic strategies for recurrent VVC.

    • Main Results:

    • Topical polyenes and imidazoles achieve >90% short-term mycological cure rates.
    • Recolonization and symptomatic relapse are common after topical treatment.
    • Oral fluconazole (150 mg single dose) is effective, well-tolerated, and safe.
    • Intermittent prophylaxis can reduce symptomatic episodes in recurrent VVC.

    Conclusions:

    • Improved understanding of VVC aids patient management and antifungal therapy selection.
    • Oral fluconazole offers a well-accepted and effective treatment option.
    • Prophylaxis is a viable strategy for managing chronic or recurrent vulvovaginal candidosis.